Improving Protein Capture for Transgenic Drug Processing

One of the greatest challenges facing biopharmaceutical manufacturers has been the primary recovery of recombinant materials from transgenic sources. As an alternative to existing methods, vibrating membrane technology, which is widely used in food and beverage processing, recently has been adapted to biopharmaceutical applications involving transgenic biosolutions.

Articles in this issue

---

FDA Will Drive Changes for Contract Business

In the Spotlight--December

Novemember 2003

FDA Seeks Risk-Based Inspection Program

Routine Sample Size for a Retest Procedure

November 2003

Aseptic Processing Guidelines and Innovative Engineering Boost Appeal of Barrier Isolators

Clearing Regulatory Hurdles

Improving Protein Capture for Transgenic Drug Processing

Related Videos

Related Content

Advertisement

July 25th 2025

EMA Approves Lower GWP Alternative for Inhalation Medicine

Susan Haigney

The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava Aerosphere that will have a 1000-fold reduction in global warming potential compared to the current propellant.

June 25th 2024

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

July 23rd 2025

Overcoming PK/PD Modeling Challenges

Cynthia A. Challener

Artificial intelligence and machine learning can help identify complex patterns.

April 30th 2024

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

July 22nd 2025

AstraZeneca to Invest $50 Billion in US Manufacturing and R&D

Susan Haigney

The company will build a multi-billion-dollar drug manufacturing center in Virginia that will focus on chronic diseases, as well as facilities in California, Indiana, Maryland, Massachusetts, and Texas.

July 22nd 2025

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions

Patrick Lavery

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Related Content

Advertisement

July 25th 2025

EMA Approves Lower GWP Alternative for Inhalation Medicine

Susan Haigney

The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava Aerosphere that will have a 1000-fold reduction in global warming potential compared to the current propellant.

June 25th 2024

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

July 23rd 2025

Overcoming PK/PD Modeling Challenges

Cynthia A. Challener

Artificial intelligence and machine learning can help identify complex patterns.

April 30th 2024

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

July 22nd 2025

AstraZeneca to Invest $50 Billion in US Manufacturing and R&D

Susan Haigney

The company will build a multi-billion-dollar drug manufacturing center in Virginia that will focus on chronic diseases, as well as facilities in California, Indiana, Maryland, Massachusetts, and Texas.

July 22nd 2025

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions

Patrick Lavery

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.